University of California, Davis |
Diana Farmer |
Clinical Trial Stage Projects |
The CuRe Trial: Cellular Therapy for In Utero Myelomeningocele Repair |
$8,996,474 |
University of California, Davis |
Gerhard Bauer |
Conference - Manage The SPARK Annual Meeting |
The 2020 SPARK Annual Meeting |
$50,000 |
University of California, Davis |
Mehrdad Abedi |
Conference - The 2020 Alpha Stem Cell Clinic Annual Symposium |
CIRM - Leading the New Era of Living Medicines |
$60,000 |
University of California, Davis |
Diana Farmer |
Late Stage Preclinical Projects |
Placental Mesenchymal Stem Cell Augmentation of Fetal Myelomeningocele Repair |
$5,666,077 |
University of California, Davis |
Alyssa Panitch |
Inception - Discovery Stage Research Projects |
Development of treatments to improve healing of ischemic wounds |
$235,099 |
University of California, Davis |
Alice Tarantal |
Inception - Discovery Stage Research Projects |
Enhanced Branching Morphogenesis and Pluripotent Cell Lineage Differentiation for Pediatric Regenerative Therapies |
$235,800 |
University of California, Davis |
Gerhard Bauer |
Conference - Manage The SPARK Annual Meeting |
The 2018 SPARK Annual Meeting |
$39,559 |
University of California, Davis |
Mehrdad Abedi |
Alpha Stem Cell Clinics Network Expansion |
Alpha Stem Cell Clinic for Northern and Central California |
$7,905,671 |
University of California, Davis |
Deborah Lieu |
Quest - Discovery Stage Research Projects |
Microenvironment for hiPSC-derived pacemaking cardiomyocytes |
$2,042,438 |
University of California, Davis |
David Segal |
Quest - Discovery Stage Research Projects |
MSC delivery of an artificial transcription factor to the brain as a treatment for Angelman Syndrome |
$1,055,319 |
University of California, Davis |
Joseph Anderson |
Therapeutic Translational Research Projects |
Overexpression of HexA/HexB by lentivector expression in blood cells to treat Tay-Sachs and Sandhoff disease |
$883,174 |
University of California, Davis |
Gerhard Bauer |
SPARK |
Internship at a Cutting Edge CIRM-funded Stem Cell Research Facility |
$373,324 |
University of California, Davis |
Mehrdad Abedi |
Clinical Trial Stage Projects |
Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-selected CD34+ Cells in AIDS lymphoma patients |
$8,414,265 |
University of California, Davis |
Diana Farmer |
Preclinical Development Awards |
Placental Stem Cells for the In Utero Treatment of Spina Bifida |
$2,182,146 |
University of California, Davis |
Roslyn Isseroff |
Preclinical Development Awards |
Scaffold for dermal regeneration containing pre-conditioned mesenchymal stem cells to heal chronic diabetic wounds |
$4,620,144 |
University of California, Davis |
Randi Hagerman |
Conference |
Pathways of Neurodevelopmental Disorders (C8) |
$29,939 |
University of California, Davis |
J. Leach |
Tools and Technologies III |
Multi-modal technology for non-destructive characterization of bioengineered tissues |
$1,574,151 |
University of California, Davis |
Laura Marcu |
Tools and Technologies III |
Multimodal platform combining optical and ultrasonic technologies for in vivo nondestructive evaluation of engineered vascular tissue constructs |
$1,834,350 |
University of California, Davis |
Alice Tarantal |
Conference |
13th Annual Gene Therapy Symposium for Heart, Lung, and Blood Diseases |
$10,000 |
University of California, Davis |
Peter Belafsky |
Disease Team Therapy Development III |
Tissue Engineered Recellularized Laryngotracheal Implants |
$3,181,162 |
University of California, Davis |
Mark Yarborough |
Conference |
Stem Cell Research for Neurological Disorders: A Case Study in Ethical and Policy Issues in ALS Research |
$1,020 |
University of California, Davis |
Alice Tarantal |
Conference |
12th Annual Gene Therapy Symposium for Heart, Lung, and Blood Diseases |
$8,000 |
University of California, Davis |
Emanual Maverakis |
New Faculty Physician Scientist |
Tunable hydrogels for therapeutic delivery of multipotent stem cells. |
$2,771,903 |
University of California, Davis |
Alice Tarantal |
Conference |
11th Annual Gene Therapy Symposium for Heart, Lung, and Blood Diseases |
$16,850 |
University of California, Davis |
Deborah Lieu |
Basic Biology IV |
Induction of Pluripotent Stem Cell-Derived Pacemaking Cells |
$1,333,689 |
University of California, Davis |
John Laird |
Disease Team Therapy Development - Research |
Phase I study of IM Injection of VEGF-Producing MSC for the Treatment of Critical Limb Ischemia |
$3,728,384 |
University of California, Davis |
Nancy Lane |
Disease Team Therapy Development - Research |
Treatment of non-traumatic osteonecrosis with endogenous Mesenchymal stem cells |
$19,606,481 |
University of California, Davis |
Vicki Wheelock |
Disease Team Therapy Development - Research |
MSC engineered to produce BDNF for the treatment of Huntington's disease |
$8,924,235 |
University of California, Davis |
Walter Boyd |
Early Translational III |
Extracellular Matrix Bioscaffold Augmented with Human Stem Cells for Cardiovascular Repair |
$4,631,754 |
University of California, Davis |
Kyriacos Athanasiou |
Early Translational III |
Tissue engineered cartilage from autologous, dermis-isolated, adult, stem (DIAS) cells |
$1,735,703 |
University of California, Davis |
Gerhard Bauer |
Creativity Awards |
Internship at a Cutting Edge CIRM-funded Stem Cell Research Facility |
$250,064 |
University of California, Davis |
Alice Tarantal |
Conference |
10th Annual Gene Therapy Symposium for Heart, Lung, and Blood Diseases |
$18,300 |
University of California, Davis |
John Laird |
Disease Team Therapy Planning I |
Phase I study of IM Injection of VEGF Producing MSC for the Treatment of Critical Limb Ischemia |
$76,066 |
University of California, Davis |
Vicki Wheelock |
Disease Team Therapy Planning I |
MSC engineered to produce BDNF for the treatment of Huntington's disease |
$97,564 |
University of California, Davis |
Mehrdad Abedi |
Disease Team Therapy Planning I |
Stem Cell Gene Therapy for HIV in AIDS Lymphoma Patients |
$66,880 |
University of California, Davis |
Nancy Lane |
Disease Team Therapy Planning I |
Increasing the endogenous mesenchymal stem cells to the bone surface to treat osteoporosis |
$107,750 |
University of California, Davis |
Martin Birchall |
Disease Team Therapy Planning I |
Airways for Children |
$19,800 |
University of California, Davis |
David McGee |
Patent Assistance Fund Awards |
CIRM Patent Prosecution Assistance Fund for Stem Cell Technologies - UCD |
$48,595 |
University of California, Davis |
Alice Tarantal |
Conference |
9th Annual Gene Therapy Symposium for Heart, Lung and Blood Diseases |
$12,000 |
University of California, Davis |
Mark Zern |
Early Translational II |
Liver Cell Transplantation |
$4,212,621 |
University of California, Davis |
Roslyn Isseroff |
Early Translational II |
Bone Marrow Mesenchymal Stem Cells to Heal Chronic Diabetic Wounds |
$4,629,747 |
University of California, Davis |
William Murphy |
Transplantation Immunology |
Donor natural killer (NK) cells as “veto” cells to promote donor-specific tolerance |
$1,257,601 |
University of California, Davis |
Eric Kurzrock |
Basic Biology II |
Differentiation of Human Embryonic Stem Cells into Urothelium |
$849,037 |
University of California, Davis |
Min Zhao |
Basic Biology I |
Directing migration of human stem cells with electric fields |
$816,228 |
University of California, Davis |
Jan Nolta |
Early Translational I |
Sustained siRNA production from human MSC to treat Huntingtons Disease and other neurodegenerative disorders |
$2,615,674 |
University of California, Davis |
Alice Tarantal |
Early Translational I |
In Utero Model to Assess the Fate of Transplanted Human Cells for Translational Research and Pediatric Therapies |
$3,143,392 |
University of California, Davis |
Frederick Meyers |
Research Training II |
UC Davis Stem Cell Training Program |
$4,838,291 |
University of California, Davis |
Alice Tarantal |
Tools and Technologies I |
In Vivo Imaging for the Detection and Quantitation of Transplanted Stem/Progenitor Cells in Nonhuman Primates |
$799,350 |
University of California, Davis |
Kit Lam |
Tools and Technologies I |
Discovery of adhesion ligands for pluripotent human stem cells |
$834,003 |
University of California, Davis |
Paul Knoepfler |
New Faculty II |
Molecular mechanisms governing hESC and iPS cell self-renewal and pluripotency |
$2,157,255 |
University of California, Davis |
Larry Vanderhoef |
Major Facilities |
UC Davis CIRM Institute |
$20,082,400 |
University of California, Davis |
Chong-Xian Pan |
New Faculty I |
Combinatorial Chemistry Approaches to Develop LIgands against Leukemia Stem Cells |
$2,386,409 |
University of California, Davis |
Alice Tarantal |
Shared Labs |
UC Davis Translational Human Embryonic Stem Cell Shared Research Facility |
$1,728,111 |
University of California, Davis |
Alice Tarantal |
Shared Labs |
UC Davis Translational Human Embryonic Stem Cell Shared Research Facility |
$2,000,000 |
University of California, Davis |
Mark Zern |
Comprehensive Grant |
An in vitro and in vivo comparison among three different human hepatic stem cell populations. |
$2,251,223 |
University of California, Davis |
Alice Tarantal |
Comprehensive Grant |
Preclinical Model for Labeling, Transplant, and In Vivo Imaging of Differentiated Human Embryonic Stem Cells |
$2,166,757 |
University of California, Davis |
Ebenezer Yamoah |
SEED Grant |
Hair Cells and Spiral Ganglion Neuron Differentiation from Human Embryonic Stem Cells |
$458,071 |
University of California, Davis |
A. Reddi |
SEED Grant |
hESCs for Articular Cartilage Regeneration |
$301,703 |
University of California, Davis |
Frederick Meyers |
Training Grant I-1 |
Stem Cell Research Training Grant |
$1,780,859 |